Skip to content
10-Q

Quarterly Report

ArriVent BioPharma, Inc. AVBP

0001104659-25-108847

← back to feed
Filed
Nov 10, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 7, 2025 41.28M sh
Shares Diluted Q3 2025 · Sep 30, 2025 41.91M sh
Shares Diluted Q3 2025 · Sep 30, 2025 36.97M sh
Shares Diluted Q3 2025 · Sep 30, 2024 33.58M sh
Shares Diluted Q3 2025 · Sep 30, 2024 30.72M sh
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$129.93M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$54.06M
Short Term Investments Q3 2025 · Sep 30, 2025 $187.59M
Short Term Investments Q3 2025 · Dec 31, 2024 $144.57M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $112.67M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $74.29M
Stockholders Equity Q3 2025 · Sep 30, 2025 $305M
Stockholders Equity Q3 2025 · Jun 30, 2025 $249.87M
Stockholders Equity Q3 2025 · Mar 31, 2025 $202.54M
Stockholders Equity Q3 2025 · Dec 31, 2024 $257.65M
Stockholders Equity Q3 2025 · Sep 30, 2024 $277.49M
Stockholders Equity Q3 2025 · Jun 30, 2024 $296.66M
Stockholders Equity Q3 2025 · Mar 31, 2024 $317.72M
Stockholders Equity Q3 2025 · Dec 31, 2023 −$153.19M
Current Liabilities Q3 2025 · Sep 30, 2025 $21.56M
Current Liabilities Q3 2025 · Dec 31, 2024 $17.27M
Total Liabilities Q3 2025 · Sep 30, 2025 $21.56M
Total Liabilities Q3 2025 · Dec 31, 2024 $17.29M
Current Assets Q3 2025 · Sep 30, 2025 $321.22M
Current Assets Q3 2025 · Dec 31, 2024 $226.98M
Total Assets Q3 2025 · Sep 30, 2025 $326.56M
Total Assets Q3 2025 · Dec 31, 2024 $274.94M
Eps Diluted Q3 2025 · Sep 30, 2025 −$0.83
Eps Diluted Q3 2025 · Sep 30, 2025 −$3.54
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.61
Eps Diluted Q3 2025 · Sep 30, 2024 −$1.95
Eps Basic Q3 2025 · Sep 30, 2025 −$0.83
Eps Basic Q3 2025 · Sep 30, 2025 −$3.54
Eps Basic Q3 2025 · Sep 30, 2024 −$0.61
Eps Basic Q3 2025 · Sep 30, 2024 −$1.95
Sga Expense Q3 2025 · Sep 30, 2025 $6.15M
Sga Expense Q3 2025 · Sep 30, 2025 $17.54M
Sga Expense Q3 2025 · Sep 30, 2024 $4.14M
Sga Expense Q3 2025 · Sep 30, 2024 $11.76M
Rd Expense Q3 2025 · Sep 30, 2025 $32.17M
Rd Expense Q3 2025 · Sep 30, 2025 $121.18M
Rd Expense Q3 2025 · Sep 30, 2024 $20.09M
Rd Expense Q3 2025 · Sep 30, 2024 $58.84M
Net Income Q3 2025 · Sep 30, 2025 −$34.98M
Net Income Q3 2025 · Sep 30, 2025 −$130.76M
Net Income Q3 2025 · Jun 30, 2025 −$31.4M
Net Income Q3 2025 · Mar 31, 2025 −$64.39M
Net Income Q3 2025 · Sep 30, 2024 −$20.56M
Net Income Q3 2025 · Sep 30, 2024 −$59.86M
Net Income Q3 2025 · Jun 30, 2024 −$21.87M
Net Income Q3 2025 · Mar 31, 2024 −$17.42M
Operating Income Q3 2025 · Sep 30, 2025 −$38.32M
Operating Income Q3 2025 · Sep 30, 2025 −$138.71M
Operating Income Q3 2025 · Sep 30, 2024 −$24.23M
Operating Income Q3 2025 · Sep 30, 2024 −$70.6M